Erasca, Inc. (NASDAQ:ERAS - Get Free Report) has received an average rating of "Moderate Buy" from the twelve brokerages that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and nine have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $23.17.
A number of analysts have commented on ERAS shares. HC Wainwright boosted their price target on shares of Erasca from $18.00 to $22.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Leerink Partners initiated coverage on shares of Erasca in a research note on Tuesday, November 17th. They issued an "outperform" rating and a $35.00 price target for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Erasca in a report on Tuesday, September 8th. Bank of America raised their price objective on shares of Erasca from $18.00 to $20.00 and gave the company a "neutral" rating in a research note on Friday, August 14th. Finally, Guggenheim boosted their target price on Erasca from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Thursday, August 13th.
View Our Latest Stock Report on Erasca
Hedge Funds Weigh In On Erasca
Several hedge funds have recently modified their holdings of the company. Nykredit A S bought a new stake in shares of Erasca in the 2nd quarter worth $29,000. Allworth Financial LP acquired a new stake in shares of Erasca in the second quarter valued at $34,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Erasca by 77.8% in the first quarter. EverSource Wealth Advisors LLC now owns 4,249 shares of the company's stock valued at $69,000 after buying an additional 1,859 shares during the period. Integrated Wealth Concepts LLC bought a new position in Erasca during the second quarter valued at about $80,000. Finally, KBC Group NV bought a new position in Erasca during the first quarter valued at about $81,000. 67.78% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about Erasca
Here are a few of the latest headlines about ERAS:
- Positive Sentiment: At the 32 mg daily dose, ERAS-0015 produced confirmed response rates of 44% in second-line-or-later pancreatic cancer patients with KRAS G12X mutations, 69% in the G12D/G12V pancreatic subgroup, and 60% in a small group of previously treated KRAS-mutant lung cancer patients. Erasca said the drug was generally well tolerated, with mostly low-grade side effects. Erasca Phase 1 data
- Positive Sentiment: The company plans to begin a potentially registration-enabling lung cancer trial and a Phase 3 pancreatic cancer trial in 2027. It also reported preliminary activity and favorable tolerability for ERAS-4001, another investigational drug, and expects to test it in combination with ERAS-0015. These developments could expand the pipeline’s potential, although they remain early-stage. Trial update
- Neutral Sentiment: A Seeking Alpha contributor upgraded Erasca to “Buy,” citing ERAS-0015’s clinical progress and the company’s Bristol Myers Squibb collaboration. This is an individual analyst opinion, not a company announcement or a consensus rating. Seeking Alpha analysis
Erasca Stock Performance
Shares of ERAS opened at $13.61 on Friday. Erasca has a one year low of $2.75 and a one year high of $24.28. The stock's fifty day moving average is $14.77 and its 200-day moving average is $15.35. The firm has a market capitalization of $4.78 billion, a price-to-earnings ratio of -13.75 and a beta of 0.68.
Erasca (NASDAQ:ERAS - Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Analysts forecast that Erasca will post -0.53 EPS for the current fiscal year.
About Erasca
(
Get Free Report)
Erasca, Inc. is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on the RAS/MAPK signaling pathway, which is involved in the growth of many tumors and can be difficult to target with existing therapies. The company's pipeline includes investigational drug candidates designed to inhibit RAS proteins and other targets in the pathway. Erasca evaluates these candidates for potential use across multiple cancer types; its medicines remain in development rather than being marketed as approved treatments.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Erasca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Erasca wasn't on the list.
While Erasca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.